A Reflection on Blood Cancer Awareness Month: Patient Spotlight

Drug Discovery

Antibody Therapeutics

Identifying Antibodies for Therapeutic Use

TruAB™ is Adaptive’s high-throughput antibody discovery process. TruAB enables rapid identification and selection of potent, naturally occurring, entirely human antibodies for clinical development and commercialization.

Differentiators of Adaptive’s Approach

Two-tone-icon--Versatility-

Versatility

  • Use B cells from human blood
  • Sourced from humanized mice
Two-tone-icon--Safety-01

Safety

  • De-risked for manufacturing and developability
  • Likely favorable safety profile
Two-tone-icon--Selection

High-throughput, high sensitivity

  • Hundreds of thousands of antibodies at a time
  • Select likely winners using bioinformatics
  • Accurate BCR heavy/light pairs at unprecedented scale
  • Screen for natural human antibodies
Two-tone-icon--T-Cell

Best clinical candidate selection

  • Entire B-cell receptors (BCR) repertoire interrogated
  • Well-characterized, naturally optimized antibodies
  • Support rational monoclonal antibody combinations

Developing Therapeutic Antibodies Against SARS-CoV-2

Neutralizing antibodies defend healthy cells by blocking the biological function of an invading virus. 

Adaptive has identified and characterized ultra-potent, neutralizing antibodies that bind to different parts of the SARS-CoV-2 virus and can be considered for development to treat COVID-19.